Adenocarcinoma

This phase 1 trial tests a gene therapy that helps prostate cancer cells absorb more radioactive iodine, potentially killing them while sparing healthy tissue. The study enrolls men whose prostate cancer returned after prior radiation therapy. Researchers aim to find the safest d…

This early-stage trial is testing a personalized vaccine made from a patient's own immune cells (dendritic cells) to treat prostate cancer. The vaccine is designed to teach the immune system to recognize and attack cancer cells by targeting multiple tumor antigens. The study invo…

Researchers are testing whether adding vorinostat to standard vinorelbine is safe and tolerable in adults with advanced solid tumors. The trial enrolls about 30 people and escalates the vorinostat dose in small groups to find the highest dose patients can take without severe side…

Researchers are testing an experimental oral drug called RVU120 in adults with advanced or metastatic solid tumors that have worsened after standard treatments. The trial has two parts: first, they check safety and find the best dose; second, they measure how well the drug shrink…

This study tested a combination of an immunotherapy drug (nivolumab) and low-dose chemotherapy in children and teenagers whose solid tumors had not responded to standard treatments. The goal was to see if the combination was safe and could help control the cancer. The trial was s…

This study tested giving immunotherapy drugs before surgery to people with liver cancer that could be removed. The goal was to see if these drug combinations could shrink the tumor or eliminate it before the operation. 62 participants took part in this early-phase trial, which ha…

This clinical trial is testing whether adding a targeted drug called bemarituzumab to standard chemotherapy and immunotherapy (nivolumab) helps people with advanced stomach or gastroesophageal junction cancer live longer. The study includes 515 adults whose tumors overexpress a p…

This early-stage trial tested a new antibody drug called GEN1057 in 23 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and see how the drug behaves in the body. The study was terminated early, so results ar…

Researchers are testing an experimental drug called MRG003 in adults with advanced gastric or gastroesophageal junction cancer that has spread or cannot be removed by surgery. The trial enrolls people whose tumors test positive for EGFR and negative for HER2, a combination that l…

This trial tests a new antibody called acasunlimab, alone or with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The study has two parts: first to find safe doses, then to see how well those doses work. About 429 participa…

This phase 2 trial is testing whether adding an experimental drug called evorpacept to two existing cancer drugs (cetuximab and pembrolizumab) can shrink tumors in people with a specific type of advanced colorectal cancer that has not responded to prior treatments. The study enro…

This study tested whether adding two drugs (lenvatinib and pembrolizumab) to a standard liver cancer treatment called TACE helps people with liver cancer that cannot be removed by surgery. About 479 participants received either the drug combo plus TACE or TACE alone. The goal was…

This early-phase trial tested ASP1012, a virus engineered to infect and kill cancer cells while making them visible to the immune system. It was given alone or with the immunotherapy pembrolizumab to 15 adults with advanced solid tumors. The main goals were to check safety and fi…

This phase 2 trial is testing whether giving two chemotherapy drugs (docetaxel and carboplatin) followed by a maintenance drug called rucaparib can help men with metastatic castration-resistant prostate cancer that has specific DNA repair defects. The idea is that the chemo shrin…

This phase 2 trial investigates whether taking the drug sunitinib for one year after surgical removal of lung metastases can improve relapse-free survival in patients with clear cell kidney cancer. Participants are randomly assigned to receive either sunitinib or a placebo follow…

This trial tests a new biologic called CSR02-Fab-TF, given directly into the liver's blood supply, for people with intermediate or limited advanced liver cancer that has not responded to prior treatment. The drug is designed to block blood vessels that feed the tumor while sparin…

This study tests whether specially engineered immune cells (EIE) can safely fight cancer. Researchers take a patient's own immune cells, modify them to target tumor-related markers, and infuse them back. The trial involves 100 people with various cancers whose tumors show specifi…

This study looked at a combination of two drugs, talazoparib and temozolomide, in 16 men with advanced prostate cancer that had spread and stopped responding to hormone therapy. The goal was to find the safest dose and see if the drugs could shrink tumors. The study was completed…

This early-phase trial tested a combination of two oral drugs, mirdametinib and brimarafenib, in 23 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to check safety, find the best dose, and see if the combo could shrink tumors. Th…

This study tests a new drug, CBX-12, in 40 women with ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if CBX-12 can shrink tumors and how safe it is at two different dose levels given every three weeks. Participants must have a specif…

This early-phase study tests a type of internal radiation called brachytherapy for people with large kidney tumors (4-10 cm) that cannot be removed by surgery or ablation. A small radiation source is placed directly into the tumor to kill cancer cells. The goal is to see if this …

This phase II trial tested two immunotherapy drugs, nivolumab and ipilimumab, in 10 people with a rare and aggressive kidney cancer called renal medullary carcinoma. The goal was to see if the drugs could shrink tumors or slow cancer growth. However, the study was terminated earl…

This early-phase trial tested a new oral drug called BBI-355, alone or with other targeted therapies, in people with advanced solid tumors that had extra DNA (oncogene amplifications). The study aimed to find the safest dose and check for side effects. It was terminated early, so…

This study tests a new oil called T-ACE Oil, mixed with a chemotherapy drug, for people with liver cancer that cannot be removed by surgery. The oil is injected directly into the liver's blood vessels to block them and deliver chemo to the tumor. The trial aims to see if it is sa…

This trial tested an experimental drug called ASP1570 in adults with advanced solid tumors that had spread or could not be removed by surgery. The drug aims to help the body's immune T-cells attack tumors that have become resistant. The study was in two parts: first to find a saf…

This phase 2 trial tested the drug olaparib (Lynparza) in people with advanced pancreatic acinar cell carcinoma, a rare pancreatic cancer. Participants took olaparib pills twice daily for up to 2 years. The study was terminated early after enrolling only 5 people, so it is not kn…

This early-phase trial tested a new antibody drug, GEN1055, in 21 adults with advanced solid tumors. The goal was to check safety and find the right dose when used alone or with pembrolizumab (with or without chemotherapy). The study was stopped early, but results help guide futu…

This trial is testing whether the targeted drug pemigatinib can slow or shrink a specific type of bile duct cancer (cholangiocarcinoma) that has a genetic change called FGFR2 rearrangement and cannot be removed by surgery. Participants will receive either pemigatinib as a daily p…

This early-phase trial tests whether an experimental protein called CD24Fc can help people with advanced solid tumors recover from severe immune-related side effects caused by immunotherapy. These side effects occur when the immune system attacks healthy tissues. CD24Fc is design…

This phase 2 trial aimed to see if infliximab and intravenous immunoglobulin (IVIG) could help cancer patients with severe lung inflammation that didn't respond to steroids. Only one patient was enrolled before the study was terminated, so no meaningful results were obtained. The…

This early-stage trial is testing an experimental oral drug called NXP800 in people with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, to find the safest dose and schedule, and then to see if the drug shows promise in specif…

This phase 2 trial tests whether combining high-dose IL-2 with nivolumab can shrink tumors in people with advanced melanoma or kidney cancer that has progressed despite prior anti-PD-1 therapy. Participants receive nivolumab and high-dose IL-2 in repeated cycles, and researchers …

This phase 2 trial tests a personalized vaccine made from a patient's own immune cells fused with their tumor cells, given alongside GM-CSF injections and imiquimod cream. The goal is to see if this combination can trigger a stronger immune response against ovarian, fallopian tub…

This study tested whether two immunotherapy drugs, nivolumab and ipilimumab, could shrink tumors in people with advanced liver cancer that had already been treated with another drug combination. The trial enrolled 15 adults whose cancer had spread or could not be removed by surge…

This study tested several immunotherapy-based drug combinations in 214 people with advanced stomach, gastroesophageal junction, or esophageal cancer that could not be removed by surgery or had spread. Participants received either standard chemotherapy or chemotherapy plus the imm…

This early-stage study tests a new drug called GSK3745417, given alone or with another drug (dostarlimab), in about 97 adults with advanced solid tumors that have stopped responding to standard treatments. The main goal is to find a safe dose and check for side effects. This is a…

This study tested a new antibody called ICT01 combined with low-dose interleukin-2 (IL-2) in 56 people with advanced solid tumors like colorectal, ovarian, and pancreatic cancer. The goal was to see if the combo is safe and can shrink tumors. Early results suggest it may help con…

This phase 2 trial is testing the drug rivoceranib in adults with recurrent or metastatic adenoid cystic carcinoma, a rare cancer that often starts in the salivary glands. The study aims to see if the drug can shrink tumors or slow the disease. Participants take rivoceranib table…

This study tests a new drug called bemarituzumab, given together with chemotherapy and an immunotherapy drug (nivolumab), in 72 adults with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The main goals are to check safety and see if the co…

This trial is testing whether combining an experimental IDO1 inhibitor (BMS-986205) with the immunotherapy drug nivolumab can shrink tumors or slow disease progression in people with advanced liver cancer that cannot be surgically removed. The study enrolls adults whose cancer ha…

This phase 2 trial is testing whether toripalimab, an immunotherapy drug, can shrink tumors in people with advanced stomach or gastroesophageal junction cancer that has worsened after at least two prior treatments. Participants receive toripalimab every three weeks. The main goal…

This early-phase trial tested OMX-0407, a new drug that blocks certain enzymes, in 68 adults with advanced solid tumors that had stopped responding to other treatments. The study aimed to find a safe dose and check if the drug could shrink tumors. However, the trial was terminate…

This trial is testing whether giving chemotherapy before the standard combination of chemo and radiation for rectal cancer could allow some patients to have a minor surgical procedure instead of a major one. The study enrolls adults with stage T2-T3 rectal cancer. The goal is to …

This trial tests whether an experimental drug called XNW5004, which blocks a protein that helps cancer grow, can boost the effects of the immunotherapy pembrolizumab (Keytruda) in people with advanced solid tumors that have stopped responding to standard treatments. The study inc…

This trial is testing an experimental drug called NUC-3373, a nucleotide analogue, in combination with standard cancer drugs for people with advanced solid tumors. The study has two parts: one combining NUC-3373 with pembrolizumab, and the other combining it with docetaxel. The g…

This trial is testing whether a 'watchful waiting' approach after chemotherapy and radiation can safely avoid radical surgery in people with a certain type of rectal cancer. Participants receive chemotherapy (FOLFOX) followed by chemo-radiation, and those whose tumors completely …

This early-phase trial is testing a new oral drug called zamzetoclax (GS-9716) in about 145 people with advanced solid tumors. The drug is given alone or combined with standard chemotherapies. The main goals are to find the safest dose and understand side effects. This is a safet…

This Phase 3 trial is testing whether a combination of two immunotherapy drugs, botensilimab and balstilimab, can help people with advanced colorectal cancer that can't be removed by surgery and has stopped responding to chemotherapy. About 834 participants will receive either th…

This study tests an experimental drug called ATG-031 in people with advanced solid tumors or B-cell non-Hodgkin lymphomas that have not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. Participants receive ATG-031 by infusion…

This early study tested an experimental drug called BI 765883, alone or with chemotherapy, in 8 adults with advanced pancreatic cancer. The goal was to find a safe dose and see if it helps shrink tumors. The trial was terminated early, so results are limited.

This trial tests a new cell therapy called TC-510 for people with advanced cancers that have a protein called mesothelin on their surface, including mesothelioma, ovarian cancer, and pancreatic cancer. TC-510 uses a patient's own immune cells, which are genetically modified to be…

This study aimed to see if adding focused radiation to standard chemotherapy helps people with a type of liver cancer (intrahepatic cholangiocarcinoma) that cannot be removed by surgery. Only one person enrolled before the trial was stopped early, so no meaningful conclusions can…

This study tested a new drug, GEN1286, in 23 adults with advanced solid tumors that had spread or could not be removed by surgery. The goal was to check the drug's safety and see if it could shrink tumors. The trial was stopped early, so results are limited.

This Phase 1 trial tests an experimental drug called OB318 in people with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and to understand how the body processes the drug. Researchers will also look for early signs tha…

This early-stage trial tests a new drug, [177Lu]Lu-EVS459, that delivers radiation directly to cancer cells in people with advanced ovarian or lung cancers. The study aims to see if the treatment is safe and tolerable, and to get an early look at whether it can shrink tumors. Par…

This trial tests whether adding a precise, internal radiation treatment (166Holmium microspheres) to standard immunotherapy (atezolizumab and bevacizumab) can shrink liver tumors that cannot be surgically removed. About 10 adults with unresectable hepatocellular carcinoma will re…

This early-phase study tested a new drug called BGB-53038, which blocks a family of KRAS proteins that help some cancers grow. It was given alone or with other drugs to 47 people with advanced solid tumors (like lung, colon, or pancreatic cancer) that have KRAS mutations. The mai…

This phase 2 trial tests whether combining two drugs—erlotinib and everolimus—can slow the growth of advanced pancreatic cancer in patients who have already received at least one prior treatment. The study enrolls people with unresectable or metastatic pancreatic adenocarcinoma a…

This early-stage trial tested an experimental drug called PF-08052666 in 19 people with advanced solid tumors like lung, ovarian, and pancreatic cancers that had not responded to standard treatments. The drug is designed to target and kill cancer cells. The study aimed to find a …

This early-stage study tested the drug revumenib in 42 adults with colorectal cancer or other solid tumors that had spread or come back after at least one prior treatment. The goal was to see if the drug is safe and can slow tumor growth. Researchers measured side effects, how th…

This early-phase trial tests a personalized cell therapy for people with metastatic pancreatic cancer. A patient's own T-cells are genetically modified to recognize and attack mesothelin, a protein found on many pancreatic cancer cells. Before receiving the modified cells, patien…

This trial studies a new drug called SLC-3010, given alone or with chemotherapy (gemcitabine), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to find safe doses and see if the drug can shrink tumors. The study is in two par…

This phase II trial tests a targeted radiation therapy called 188Re-SSS lipiodol for people with liver cancer that cannot be surgically removed. The treatment delivers radiation directly to the tumor through the liver's blood vessels. The study aims to see how many patients' tumo…

This trial investigates whether giving a combination of bevacizumab (a drug that blocks blood vessel growth to tumors) and chemotherapy before surgery can eliminate all signs of cancer in people with stage II or III rectal cancer. Participants receive the treatment before their p…

This early-stage trial is testing whether dapagliflozin (Farxiga), a drug used for diabetes and heart failure, is safe and tolerable when taken for four weeks before prostate removal surgery in men with localized prostate cancer. The study will also look for signs that the drug m…

This phase 2 trial tested the immunotherapy drug nivolumab (Opdivo) given before and after a procedure called electroporation for people with advanced hepatocellular carcinoma (liver cancer) that could still be treated with curative intent. The study aimed to see if adding nivolu…

This phase 3 trial aimed to compare two drugs, ribociclib and palbociclib, in people with a specific type of advanced breast cancer (HR+/HER2- with HER2-enriched features). Participants received one of the drugs combined with hormone therapy. The goal was to see which combination…

This early-phase trial is testing whether adding two immunotherapy drugs (botensilimab and balstilimab) to a strong chemotherapy mix plus two oral medications (chloroquine and celecoxib) can help people with metastatic pancreatic cancer that hasn't been treated yet. The study inv…

This early-phase trial tested a two-step chemotherapy approach for people with a type of liver cancer (intrahepatic cholangiocarcinoma) that cannot be surgically removed. First, patients received a standard chemo mix (mFOLFIRINOX) through the veins. Then, they got a second chemo …

This early-stage study tested a new drug called Debio 0123 in 66 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find the safest dose and to check for side effects and any signs that the drug could shrink tumors. The st…

This study tested a drug called bemarituzumab in 260 adults with solid tumors that have high levels of a protein called FGFR2b. The main goals were to see if the drug is safe and if it can shrink tumors. Participants had already tried other treatments without success.

This phase I trial tested radiation therapy in 36 patients with liver cancers (hepatocellular carcinoma, cholangiocarcinoma, or metastases) who also have impaired liver function from cirrhosis, chemotherapy, or surgery. The goal was to find the safest dose and understand side eff…

This study aimed to compare two standard treatments for people with large intermediate-stage liver cancer that cannot be surgically removed. One group would receive a combination of two immunotherapy drugs (atezolizumab and bevacizumab), while the other would receive local treatm…

This early-stage study tested a new drug called CLN-617, alone or with the immunotherapy Keytruda, in 23 adults with advanced solid tumors that had not responded to standard treatments. The goal was to check safety and find the right dose. However, the trial was terminated, so fu…

This study looked at whether adding a precise type of radiation (stereotactic body radiation therapy) to standard chemotherapy could better control pancreatic cancer that has spread to only a few spots in the body. The trial planned to enroll patients with limited metastases, but…

This study tested a new drug called PRS-344/S095012 in people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. The trial was stopped early, and only 46 people took part.

This early-stage study tested a new drug called VVD-130850, which blocks a protein (STAT3) that helps cancers grow. The trial aimed to find a safe dose and see if the drug works, both alone and with another immunotherapy, in people with advanced solid tumors or blood cancers. The…

This early-stage study tested a new drug called PF-07265807 in people with advanced or metastatic solid tumors that had spread. The main goals were to find a safe dose and check for side effects. The trial was terminated early, so results are limited.

This study tested whether combining weight management (diet and exercise guidance) with a daily hormone pill (megestrol acetate) could help obese patients with early-stage endometrial cancer who want to preserve their fertility. The goal was to see if the cancer would completely …

This study tested a combination of two drugs, pembrolizumab and lenvatinib, in 18 adults with melanoma or kidney cancer that had spread to the brain. Participants had already received anti-PD-1/PD-L1 therapy. The goal was to see if the drug combo could shrink or eliminate brain t…

This study tested a new drug (INCB099280) combined with a standard cancer drug (axitinib) in adults with advanced solid tumors that had stopped responding to other treatments. The main goals were to check safety and see if the combination could shrink tumors. The trial was termin…

This phase 3 trial tested a combination of two targeted drugs, alpelisib and olaparib, against standard chemotherapy in 358 women with a tough-to-treat type of ovarian cancer that had stopped responding to platinum-based chemotherapy. The study only included women without a BRCA …

This early-stage trial tested a new drug called 2X-121, alone and combined with another drug called dovitinib, in 14 people with advanced solid tumors. The goal was to find the safest dose and check for side effects. The study was terminated early, so results are limited and no c…

This early-phase study tested a new drug called eciskafusp alfa, alone or with another immunotherapy (atezolizumab), in 189 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. The study…

This phase 3 trial tested whether adding the immunotherapy drug atezolizumab to standard chemotherapy and HER2-targeted therapy could help people with HER2-positive breast cancer that has spread. The study enrolled 190 participants but was terminated early, so the full results ar…

This study aimed to see if combining two drugs, bemcentinib and pacritinib, could help people with advanced lung adenocarcinoma that had stopped responding to other treatments. Only 4 patients were enrolled before the study was terminated early, so no conclusions can be drawn abo…

This study tested a new drug called LSTA1 added to standard treatment for people with advanced bile duct or gallbladder cancer. The goal was to see if the combination is safe and works better than standard treatment alone. The trial was stopped early, and results are not yet avai…

This early-stage study tested a new cancer pill (PF-07985045) alone or with other drugs in people with advanced solid tumors that have a KRAS gene mutation. The trial included patients with lung, colon, or pancreatic cancer. The study aimed to check safety and find the right dose…

This early-phase trial tested a new immunotherapy called BI 1821736 in 10 adults with advanced solid tumors that had not responded to standard treatments. BI 1821736 is a specially designed virus meant to kill cancer cells and help the immune system fight the cancer. Participants…

This phase III trial compared two radiation strategies for cancer that had spread to the brain and returned in new spots after initial radiosurgery. One group received focused radiation only to the new tumors, while the other received whole brain radiation that avoided the memory…

This early-phase trial tested combinations of the drugs bevacizumab and temsirolimus, sometimes with valproic acid or cetuximab, in 154 people with advanced cancers or certain non-cancerous but progressive diseases. The main goal was to find safe doses and look for any signs that…

This early-phase trial tested an oral drug called DT-9081 in 29 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to find a safe dose and check for side effects. The study was terminated early, so full results are not available.

This early-stage study tested a new drug called NM6603 in 17 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find the safest dose and check for side effects. The trial was ended early, so results are limited.

This study tested two immunotherapy drugs (durvalumab and tremelimumab) in people with liver cancer who were waiting for a liver transplant. The goal was to see if the drugs could safely shrink tumors and control the disease without causing organ rejection. Only 8 people took par…

This study tested a combination of chemotherapy drugs for people with stomach cancer that has spread inside the belly. The treatment involved giving one drug directly into the abdomen and through a vein, plus a second drug taken by mouth. The goal was to see if this approach coul…

This early-stage trial tested a new drug called AXN-2510 in adults with advanced solid tumors that had stopped responding to other treatments. The drug is a special antibody that targets two cancer pathways at once. However, the study was terminated early after enrolling only 3 p…

This study tested a new drug called PF-08046052/SGN-EGFRd2 in people with advanced solid tumors that could not be removed or had spread. The goal was to find a safe dose and check for side effects. The trial was terminated early, and it included people with colorectal, lung, head…

This study tested a combination of two drugs, donafenib and KN046, in people with advanced gastrointestinal cancers that had not responded to standard treatments. The goal was to check safety and see if the drugs could shrink tumors. The trial was stopped early, and only 15 peopl…

This early-phase trial tested the drug plinabulin combined with radiation and immunotherapy in 19 people with advanced cancers (like lung, bladder, or melanoma) that had stopped responding to standard immunotherapy. The goal was to see if the combination was safe and could shrink…

This study tested whether adding an experimental drug (VIC-1911) to the standard drug lenvatinib could help people with liver cancer that no longer responds to lenvatinib alone. Only 5 people were enrolled before the study was stopped early. The goal was to see if the combination…

This study tested a new drug called serabelisib combined with a diet that lowers insulin levels, with or without another chemotherapy drug, in people with advanced solid tumors that have a specific genetic change (PIK3CA mutation). The goal was to see if the diet could reduce sid…

This early-phase study tested a personalized cell therapy made from a patient's own tumor-fighting immune cells. It aimed to see if the treatment was safe for people with advanced solid tumors that had spread or come back. Only 2 people took part before the study was stopped earl…

This study tested a precision medicine approach for people with advanced cancers like breast, ovarian, pancreatic, prostate, or sarcoma. Researchers used genetic and protein tests to track how the cancer changes and then a team of experts recommended personalized drugs. The goal …

This early-phase trial tested a personalized treatment called GT201 for people with advanced solid tumors that had spread or returned. The therapy uses a patient's own immune cells (tumor-infiltrating lymphocytes) that are collected from a tumor, multiplied in a lab, and then inf…

This early-phase trial tested a personalized therapy called GT201, made from a patient's own tumor-fighting immune cells (TILs), for advanced solid tumors. Only 6 people were enrolled before the study was terminated. The treatment involved intensive chemotherapy followed by infus…

This study tested the drug lenvatinib in people whose liver cancer came back after a liver transplant. The goal was to see if the drug could shrink tumors. Only 3 people joined before the study was stopped early, so we have very limited information on how well it works.

This early-stage study tested a new drug called NB004 in 25 adults with advanced solid tumors that had no standard treatment options. The main goal was to check the drug's safety and how the body processes it. The study was terminated early, so results are limited.

This early-stage study tested an experimental oral drug called M1069 in 15 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. The trial was terminated early, so results are limited and…

This early-phase study tested a new drug called BPT567 in 20 adults with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to help the immune system fight cancer by targeting PD-1 and delivering an immune-boosting protein (IL-18). The …

This phase 2 trial tested whether combining metformin (a diabetes drug) with doxycycline (an antibiotic) could help treat localized breast and uterine cancers. The study enrolled 29 people who were scheduled for surgery. Researchers looked at changes in certain proteins in the tu…

This study tested whether matching specific targeted drugs to the genetic changes in a person's ALK-positive lung cancer could improve treatment. It included 10 adults with advanced non-small cell lung cancer that had already been treated. The trial was stopped early due to low e…

This early-stage study tested a new drug called PF-08046037, alone or with another drug (sasanlimab), in 8 people with advanced lung, pancreatic, melanoma, or head & neck cancers. The goal was to check safety and how the body handles the drugs. The trial was terminated early, so …

This early-stage trial tested a personalized treatment called GTE-001, which uses immune cells taken from a patient's own tumor to attack their cancer. It was designed for people with advanced lung adenocarcinoma that had stopped responding to standard chemotherapy. However, the …

This early-phase trial tested a three-drug combination (ivosidenib, nivolumab, and ipilimumab) in 7 people with advanced bile duct cancer that has a specific IDH1 mutation. The goal was to check safety and find the right dose, but the study was stopped early by the sponsor before…

This phase 2 study tested three doses of the experimental drug AUR109 in 29 adults with advanced colorectal, ovarian, or kidney cancer who had already tried at least two other treatments. The goal was to see if the drug could shrink tumors and to check its safety. The trial was t…

This very early trial tested two immune-stimulating drugs injected directly into tumors for people with stage IV pancreatic cancer. The goal was to see if the combination could shrink tumors or slow their growth. However, the study was stopped early after enrolling only 2 partici…

This early-stage trial tested an oral drug called AUR105 in 17 adults with advanced solid tumors or lymphomas that had not responded to prior treatments. The study aimed to find a safe dose and check how the drug moves through the body. However, the trial was terminated, so resul…

This early-stage trial tested a new drug called AUR103 calcium, given together with standard treatments (trastuzumab and chemotherapy), for people with advanced HER2-positive stomach or gastroesophageal junction cancer. The study aimed to find a safe dose and check if the combina…

This early-phase study tested a new drug called AUR103 Calcium in 27 adults with advanced solid tumors, acute myeloid leukemia, myelodysplastic syndromes, or non-Hodgkin lymphoma who had no other treatment options. The goal was to find the best dose and check safety. The study wa…

This study tested several drug combinations in 40 people with advanced stomach or gastroesophageal junction cancer that had not been treated before. The goal was to see which combinations shrank tumors. The study was terminated early, so results are limited.

This phase 1 study tested the cancer drug pazopanib in 18 frail elderly patients (aged 75+) with metastatic cancers like kidney, lung, or breast cancer. The goal was to find the highest safe dose by starting at 400 mg daily and increasing if tolerated. The study was terminated ea…

This study tested an experimental oral drug called TNG908 in people with advanced solid tumors that have lost a gene called MTAP. The goal was to see if the drug is safe and can shrink tumors. The study was planned for up to 192 participants but was terminated early, so results a…

This early-phase trial tested a personalized cell therapy called ITIL-306 in people with advanced ovarian, lung, or kidney cancers that had not responded to standard treatments. The therapy uses a patient's own immune cells (TILs) taken from their tumor, modified to better attack…

This study tested whether surgically removing both the main pancreatic tumor and any limited spread to the liver or lungs could help people with pancreatic cancer live longer. Only 5 people enrolled before the trial was stopped early. Participants first received chemotherapy, the…

This study tested whether a drug called TNK (tenecteplase) could help drain loculated (pocketed) fluid from the chest in cancer patients better than a saltwater solution. The trial planned to enroll about 20 adults with cancer and a chest tube already in place. However, the study…

This early-stage trial tested an investigational drug called TransCon TLR7/8 agonist, alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors that could not be cured by surgery or radiation. The study aimed to find a safe dose and check for side effect…

This study tested whether combining two drugs, trametinib and hydroxychloroquine, could help overcome treatment resistance in people with advanced pancreatic cancer that had spread. The trial aimed to see how many patients were free of cancer growth after 12 weeks. It included 20…

This study compared two types of radiation given after breast-conserving surgery for early-stage breast cancer: 3D conformal radiation (external beams) and internal brachytherapy (radioactive material placed in the breast). Only 6 women took part before the trial was stopped earl…

This early-phase trial tested a new drug called BAT8007 in 93 people with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to target a protein called Nectin-4 on cancer cells and deliver a chemotherapy agent directly to them. The main…

This early-stage study tested a new drug called DR30303 in 13 people with advanced digestive system cancers that had stopped responding to standard treatments. The drug is a lab-made antibody designed to target a protein called CLDN18.2 found on some cancer cells. The main goals …

This study aimed to compare two different ways of giving chemotherapy (FLOT) to people with stomach or gastroesophageal junction cancer. One group received all chemotherapy before surgery, while the other received some before and some after surgery. The study was stopped early af…

This early-stage study tested a new drug combination (MGN1703 plus ipilimumab) in people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find the safest dose of MGN1703 when given with ipilimumab. The study was stopped early, bu…

This early-stage study tested a new drug called CPO-100 in 34 adults with advanced solid tumors that had not responded to at least two prior treatments. The goal was to check safety and find the right dose. The study was terminated early, so results are limited.

This study tested whether injecting chemotherapy drugs directly into pancreatic cysts could shrink or eliminate them. It involved 75 adults with cysts between 2-5 cm. The approach used an endoscope to guide the injection, comparing two different pre-treatment rinses. The trial wa…

This phase 2 trial tested a liver-directed chemotherapy using idarubicin mixed with lipiodol (a fatty contrast agent) injected directly into the liver artery. The goal was to see if this could control non-spreading liver cancer in 44 patients with cirrhosis. The study was termina…

This study tested whether a nutritional drink called Impact Oral®, taken for 5 days before and after surgery, could reduce complications in colorectal cancer patients. The trial included 71 patients eligible for minimally invasive surgery. However, the study was terminated early,…

This early-phase trial tested a new drug called nanrilkefusp alfa, which helps activate immune cells, both alone and combined with the immunotherapy pembrolizumab. It included 115 people with various advanced solid tumors that had stopped responding to standard treatments. The st…

This early-stage study tested a new drug, HMPL-306, in 42 adults with advanced solid tumors that have an IDH mutation. The goal was to find a safe dose and check for side effects. The study was terminated early, so results are limited and no cure is expected.

This early-stage trial tested an experimental immunotherapy called IMU-201 (PD1-Vaxx) in 24 adults with advanced non-small cell lung cancer. The treatment was given alone or combined with another immunotherapy drug (atezolizumab) and sometimes chemotherapy. The goal was to check …

This study tested a new gel called Dehisgel in 20 adults who had colorectal surgery for rectal cancer. The goal was to see if the gel could safely prevent leaks where the bowel was reconnected. The study was stopped early, so results are limited.

This study aimed to see if injecting radioactive particles (OncoSil) directly into pancreatic tumors during an endoscopic ultrasound, combined with chemotherapy, could safely shrink tumors and improve survival. It was designed for people with advanced pancreatic cancer that could…

This early-phase study tested a new drug called PF-07921585, given alone or with another drug (sasanlimab), in adults with advanced solid tumors like lung, bladder, kidney, melanoma, head & neck, or colorectal cancer. The goal was to check safety and find the right dose. Only 4 p…

This study tested a combination of two drugs, sitravatinib and nivolumab, in people with advanced kidney cancer that had spread and worsened after prior treatment. The goal was to see if the combination could shrink tumors or slow the disease. The study was stopped early after en…

This early-phase study tested an experimental drug called DS-9606a in 88 people with advanced solid tumors that have a specific protein (Claudin-6). The main goal was to check safety and find the right dose. The trial was terminated, meaning it stopped before completion, so we ha…

This early-phase study tested an experimental drug called BR105 in 31 adults with advanced cancers that no longer responded to standard treatments. The main goals were to check safety, find the right dose, and see if the drug could shrink tumors. The trial was stopped early, so r…

This study tested a temporary biodegradable balloon placed between the prostate and rectum during radiation therapy for intermediate-risk prostate cancer. The goal was to see if the balloon could reduce radiation damage to the rectum by pushing it away from the prostate. The stud…

This early-stage trial tested a new oral drug, AZD0022, designed to block the KRASG12D mutation found in some advanced cancers like lung, pancreatic, and colorectal cancer. The study aimed to see if the drug was safe and tolerable when given alone or with another cancer drug (cet…

This phase 3 study tested whether adding atezolizumab (an immunotherapy) to cabozantinib (a targeted therapy) helps people with advanced kidney cancer whose disease worsened after prior immunotherapy. The trial enrolled 522 participants but was terminated early, so the full benef…

This study tested a combination of two drugs, apalutamide and abiraterone, along with prednisone, in men whose prostate cancer had spread and stopped responding to standard hormone therapy. The goal was to see if this combination could slow cancer growth. Only 7 men took part bef…

This early-phase study tested a new drug called GEN2, given with another drug (valganciclovir), in 37 adults with advanced solid tumors that had stopped responding to other treatments. The goal was to find a safe dose and check for side effects. The study was terminated, so resul…

This study tested a new experimental drug, BGB-A3055, alone or with another drug (tislelizumab), in people with advanced or metastatic solid tumors. The goal was to check safety, how the body handles the drug, and any early signs of tumor shrinkage. The study was stopped early, b…

This phase II trial tested two immunotherapy drugs, durvalumab and tremelimumab, in 79 patients with advanced thyroid cancer that had progressed despite treatment. The goal was to see if the combination could slow or stop cancer growth. The study was terminated early, so the full…

This study tested two immunotherapy drugs, AK119 and AK112, with or without chemotherapy, in 59 people with a specific type of advanced lung cancer (EGFR-mutant non-squamous NSCLC) that had stopped responding to standard targeted pills. The goal was to see if the combination was …

This phase 3 trial compared a combination of two drugs (regorafenib and pembrolizumab) with standard locoregional therapies (TACE or TARE) as a first treatment for intermediate-stage liver cancer that has spread beyond certain limits. The study aimed to enroll about 496 people bu…

This phase 3 study tested a new drug called pralsetinib against standard chemotherapy for people with a specific type of advanced lung cancer that has a RET gene fusion. The goal was to see if pralsetinib could better delay cancer growth. The trial was terminated early, so full r…

This early-phase study tested a new treatment for adults with advanced solid tumors that had not responded to standard therapies. The treatment combined a cancer-killing virus (onCARlytics) with an immune-boosting drug (blinatumomab), given either into the tumor or through a vein…

This early-stage study tested a new treatment called VAXINIA (CF33-hNIS), a virus designed to attack cancer cells, in 66 adults with advanced solid tumors that had spread. The treatment was given alone or with the immunotherapy drug pembrolizumab, either as a shot into the tumor …

This study aimed to see if adding electromagnetic fields to the drug regorafenib could help people with advanced liver cancer live longer without their cancer growing. It was designed for patients who had already tried other treatments. However, the study was stopped early after …

This study tested two drugs (toripalimab and lenvatinib) given before and after kidney cancer surgery in people with different stages of kidney cancer. The goal was to see if the treatment could shrink or eliminate the tumor before surgery and keep cancer from coming back after. …

This study tested a drug called PRO1160 in people with advanced kidney cancer, nasopharyngeal cancer, or non-Hodgkin lymphoma. The goal was to find a safe dose and see if the drug shrinks tumors. The trial was stopped early, so results are limited.

This early-phase trial tested an oral drug called DCC-3084, alone or with other cancer treatments, in 29 people with advanced solid tumors that have MAPK pathway mutations (like certain lung, pancreatic, or skin cancers). The study aimed to find safe doses and see if tumors shrin…

This study tested a new drug (BMS-986218) plus nivolumab and targeted radiation in people with advanced solid tumors that had spread. The goal was to see if this combination could help the immune system fight cancer better. Only 13 people took part before the study was stopped ea…

This early-stage trial tested a new drug called DFF332, which targets a protein (HIF2α) that helps some cancers grow. The study included 40 adults with advanced clear cell renal cell carcinoma or other cancers with specific gene changes. DFF332 was tested alone and in combination…

This phase 2 trial tested whether MRI-guided radiation therapy, given in fewer but higher doses, could safely treat high-risk prostate cancer while reducing side effects. The study enrolled 6 men with localized, high-risk prostate cancer who also received standard hormone therapy…

This early-stage study tested a new oral drug, ATX-559, in 17 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find a safe dose and check for side effects. The study was terminated early, so results are limited.

This phase 2 trial tested a combination of three drugs—nivolumab (an immunotherapy), tadalafil (commonly used for erectile dysfunction), and vancomycin (an antibiotic)—in adults with liver cancer or liver metastases from colorectal or pancreatic cancers that had not responded to …

This early-stage study tested a new drug called PF-07826390, given alone or with another drug (sasanlimab), in people with advanced solid tumors like lung, kidney, and colorectal cancers. The goal was to check safety and find the right dose. Only 10 people took part, and the stud…

This early-phase study tested a new drug called BGB-24714, which is designed to help cancer cells die. It was given alone or with chemotherapy to 157 adults with advanced solid tumors that had spread or could not be removed. The main goal was to find a safe dose and see how well …

This phase II trial tested the drug poziotinib in 93 people with advanced non-small cell lung cancer that has specific changes in the EGFR or HER2 genes. The goal was to see if the drug could shrink tumors or stop them from growing. The study was terminated early, so results are …

This early-phase study tested a new drug, WBC100, in 68 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the best dose, and see how the drug moves through the body. The trial was terminated, so results…

This early-stage study tested an experimental oral drug (PF-07265028) alone or combined with an immunotherapy injection (sasanlimab) in 21 people with advanced solid tumors, including stomach, lung, and head/neck cancers. The main goals were to find a safe dose and check for side…

This early-stage trial tested a new drug, QEQ278, in 30 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check the drug's safety and find the right dose. The study was stopped early, so results are limited.

This study tested a drug called cadonilimab in people with liver cancer who had surgery to remove their tumor but were at high risk of the cancer returning. The goal was to see if the drug could help keep the cancer away. The trial was stopped early, so the full results are not y…

This phase 2 trial aimed to see if the drug niraparib could shrink tumors in people with metastatic pancreatic cancer that has certain gene mutations. Only 2 patients were enrolled before the study was terminated early, so we don't have enough information to know if it works. The…

This phase 2 trial tested the drug guadecitabine (SGI-110) in people aged 12 and older with rare cancers like wild-type GIST, pheochromocytoma, paraganglioma, and HLRCC-related kidney cancer that had not responded to other treatments. Participants received daily injections for 5 …

This early-stage trial tested a new drug called MRTX0902, alone or with another drug (adagrasib), in 64 people with advanced solid tumors that have certain gene mutations (KRAS-MAPK pathway). The main goals were to check safety and how the drug moves through the body. The trial w…

This early-phase trial tested a combination of targeted drugs (neratinib, pertuzumab, trastuzumab) and chemotherapy (paclitaxel, doxorubicin, cyclophosphamide) in 34 people with advanced or inflammatory breast cancer. The goal was to find the best dose and see if the combo could …

This early-stage trial tested a new drug called SIM0501, alone or with another drug (olaparib), in 13 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and how the drug moves through the body. The study was s…

This study tested a one-time gene therapy called Temferon in 10 people with advanced kidney cancer that had worsened after standard treatments. The goal was to see if it was safe and could activate the immune system against tumors. The trial was terminated early, so results are l…

This early-phase study tested a new drug called PRT3789 combined with the immunotherapy pembrolizumab (Keytruda) in people with advanced solid tumors that have a SMARCA4 gene mutation. The goal was to see if the combination was safe and could shrink tumors. However, the study was…

This early-stage study tested an experimental oral drug called PRT7732 in people with advanced solid tumors that have a specific genetic mutation (SMARCA4). The main goals were to check safety, find the right dose, and see if the drug could shrink tumors. The study was terminated…

This study tested a new drug combination (SON-1010 plus atezolizumab) in people with advanced solid tumors, especially platinum-resistant ovarian cancer. The goal was to see if the combination was safe and could slow tumor growth. The trial was terminated early, so results are li…

This early-phase trial tested an experimental drug called GEN1078 in 3 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check for side effects and see how the body processes the drug. The trial was terminated early, so r…

This early-phase study tested a treatment called huCART-meso cells, which are a patient's own immune cells modified to recognize and attack pancreatic cancer cells. The trial included 54 people with advanced pancreatic cancer that could not be removed by surgery. The main goal wa…

This early-phase trial tested a new therapeutic vaccine (EO2401) combined with the immunotherapy drug nivolumab in 70 people with advanced adrenocortical carcinoma or malignant pheochromocytoma/paraganglioma. The goal was to see if the combination is safe and can shrink tumors or…

This early-phase trial tested the safety and dosing of a new drug called modakafusp alfa, given alone or with pembrolizumab, in adults with advanced solid tumors or melanoma. The study aimed to find the highest safe dose and check for side effects. It was terminated early, so res…

This phase II trial tested a combination of chemotherapy infused directly into the liver (HAIC) plus two immunotherapy drugs (atezolizumab and bevacizumab) given before and after surgery for high-risk bile duct cancer. The goal was to see if this approach could shrink tumors and …

This early-stage study tested a combination of two drugs, niraparib and dostarlimab, in children and teens (ages 6 months to 17 years) with solid tumors that had come back or were not responding to treatment. The goal was to find a safe dose and see if the drugs could shrink tumo…

This early-phase trial tested a new treatment called HV-101 for people with advanced solid tumors that had spread or come back. The therapy uses a patient's own immune cells (TILs) taken from their tumor, grown in a lab, and then given back along with chemotherapy and IL-2. The s…

This early-phase trial tested an experimental drug called TAK-500, alone or with the immunotherapy pembrolizumab, in 61 adults with advanced solid tumors like pancreatic, liver, and lung cancer. The main goals were to check safety and see if the drug could shrink tumors. The stud…

This early-phase trial tested a personalized cancer treatment called tumor-infiltrating lymphocyte (TIL) therapy. Doctors took immune cells from each patient's own tumor, grew them in a lab, and infused them back to fight the cancer. The study enrolled only 5 adults with advanced…

This early-stage trial tested a new drug called RP-3467, alone or with olaparib, in 26 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. The study was terminated, so full results are no…

This study tested a new drug called SAR444200, alone or with other cancer treatments, in 33 adults with advanced solid tumors that had spread and were not responding to standard therapy. The main goals were to check safety and find the right dose. The trial was terminated early, …

This early-phase trial tested an experimental drug called OC-001, given alone or with the immunotherapy avelumab, in 73 people with various advanced or metastatic cancers (like lung, breast, and bladder cancer). The main goals were to check safety and how the drug moves through t…

This early-phase study aimed to see if combining two immune-stimulating drugs (rintatolimod and interferon alpha-2b) could help cancer patients fight off COVID-19. Only 4 people took part before the study was stopped early. The main goals were to check safety and measure how the …

This early-stage trial tested a combination of two drugs, APG-1387 and toripalimab, in 40 people with advanced solid tumors including colorectal, nasopharyngeal, and lung cancers. The goal was to find a safe dose and see if the combination could control the disease. However, the …

This study tested an experimental drug called APG-1387 combined with standard chemotherapy (gemcitabine and nab-paclitaxel) in people with advanced pancreatic cancer. The goal was to find the safest dose and see if the combination could shrink tumors. However, the trial was termi…

This study tested a new drug, felmetatug vedotin, alone or with pembrolizumab, in people with advanced solid tumors like ovarian, breast, and lung cancer. The goal was to check safety and find the right dose. The trial was terminated early, so results are limited.

This study tested a drug called Promitil in 19 people with ovarian or pancreatic cancer that had specific gene mutations (BRCA or HRD) and had stopped responding to first treatment. The goal was to see if Promitil could control tumor growth safely. The trial was terminated early,…

This study looked at whether a less invasive surgery (conservative surgery) could safely treat women with early-stage, low-risk cervical cancer. The goal was to see if this approach causes fewer side effects and helps recovery. The study included 137 women with stage IA2 or IB1 c…

This phase 2 trial tested repotrectinib with or without fulvestrant in people with a rare, hormone-positive, HER2-negative metastatic breast cancer called invasive lobular carcinoma. The goal was to see if the combination could control the disease after standard treatments had st…

This early-phase trial tested a radioactive drug designed to seek out and destroy cancer cells in people with advanced solid tumours that had stopped responding to other treatments. The drug targets a protein called IGF-1R found on many cancer cells. The study aimed to find a saf…

This phase 2 study tested a two-step treatment for colorectal cancer that had spread only to the liver and could not be removed by surgery. First, patients received radioactive beads (Holmium-166 TARE) directly into the liver, followed by maintenance chemotherapy and targeted dru…

This early-phase trial tested two experimental drugs, tuvusertib and PLX038, in 10 adults with advanced solid tumors that had not responded to standard treatments. The goal was to find a safe dose and see if the combination could shrink tumors. However, the study was terminated e…

This phase II trial tested a precise type of radiation called proton beam therapy in 9 people with liver cancer. The goal was to see if it could control the cancer while limiting damage to the liver. The study was stopped early, so the findings are limited, but early data suggest…

This study tested whether adding an experimental drug called CPI-613 (devimistat) to standard chemotherapy (gemcitabine plus cisplatin) could help people with advanced biliary tract cancer that cannot be removed by surgery. The trial had two parts: first, finding the safest dose …

This early-phase trial tested an experimental drug called IBI3004 in people with advanced solid tumors that could not be removed by surgery. The study aimed to find a safe dose and check for side effects, but it was terminated after enrolling only 5 participants. Because it stopp…

This early-stage study tested a new drug called RO7759065, alone or with another drug (atezolizumab), in 12 people with advanced solid tumors that could not be cured. The main goals were to check safety and how the drug moves through the body. The study was stopped early, so resu…

This early-stage study tested a radioactive drug called 177Lu-FF58 in 24 people with advanced pancreatic, gastroesophageal, or brain cancer. The drug seeks out and attaches to specific proteins on cancer cells to deliver radiation directly. The main goals were to check safety, fi…

This study tested whether adding surgery to chemotherapy helps people with stage IV stomach cancer that has spread to only one other area. The goal was to see if surgery could improve survival and quality of life. However, the trial was stopped early after enrolling only 6 partic…

This early-stage trial tested a new drug called NXP800 in 7 people with advanced bile duct cancer that had spread or stopped responding to treatment. The goal was to find a safe dose and see if the drug could shrink tumors by blocking a protein linked to cancer growth. However, t…

This early-phase study tested a new drug called KZR-261 in 61 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the right dose, and see if the drug could shrink tumors. The trial was terminated, but the…

This study tested whether adding a stronger chemotherapy infusion (HAIC-TACE) to the targeted drug donafenib works better than standard treatment for people with intermediate-stage liver cancer that cannot be removed by surgery. The trial was stopped early and only included 18 pa…

This early-stage trial tested a new drug called M9466 combined with standard chemotherapy in people with advanced solid tumors or colorectal cancer who had no other treatment options. Only 3 people took part before the study was stopped. The main goal was to check safety and find…

This study tested a vaccine called PROSTVAC-V/F in 33 men who had their prostate removed due to cancer and were at high risk of the cancer returning. The goal was to see if the vaccine could keep cancer from coming back. The study was stopped early, so results are limited, but it…

This phase 2 trial tested a genetically modified measles virus (MV-NIS) against standard chemotherapy in 17 women with ovarian, fallopian, or peritoneal cancer that no longer responded to platinum drugs. The virus was designed to infect and kill cancer cells while leaving healthy…

This study looked at whether two drugs, finerenone and empagliflozin, can slow kidney function decline in people at high risk for chronic kidney disease after having a kidney removed for cancer. Ten participants took one or both drugs or no drug for a year. The trial was terminat…

This early-stage trial tested a combination of two immunotherapy drugs, aldesleukin (IL-2) and pembrolizumab, in 6 people with advanced kidney cancer that had spread. The goal was to find the safest dose and see if the combination could shrink tumors. The study was terminated ear…

This early-phase trial tested whether adding the experimental drug YL-13027 to standard chemotherapy (gemcitabine and nab-paclitaxel) is safe for people with advanced pancreatic cancer that no longer responds to treatment. Only 4 participants were enrolled before the study was st…

This early-stage trial tested a new drug called RP-6306 combined with standard chemotherapy (FOLFIRI) in 38 adults with advanced solid tumors that had stopped responding to other treatments. The goal was to check safety, find the best dose, and see if the combo could shrink tumor…

This early-phase study tested an oral drug called Debio 0123 combined with the chemotherapy carboplatin in 76 people with advanced solid tumors that had stopped responding to prior platinum-based treatments. The main goals were to find a safe dose and check for side effects. The …

This early-phase study tested a new oral drug (RP-6306) combined with the chemotherapy gemcitabine in 67 adults with advanced solid tumors that had stopped responding to other treatments. The main goals were to check safety, find the best dose, and see if the combination could sh…

This early-stage study tested a new drug (JS004) combined with another immunotherapy (Toripalimab) in 31 people with advanced solid tumors like liver, esophageal, stomach, cervical, or colorectal cancer. The goal was to check safety and see if the combination could help control t…

This phase 2 trial tested a combination of two drugs, niraparib and dostarlimab, in 51 adults with advanced solid tumors that had DNA repair defects or were sensitive to platinum chemotherapy. The goal was to see if the combo could shrink tumors. However, the study was terminated…

This trial tested a combination of two drugs, rucaparib and atezolizumab, in 130 adults with advanced solid tumors that have specific DNA repair problems or are sensitive to platinum chemotherapy. The goal was to see if the combination could shrink tumors. However, the study was …

This early-phase trial tested a new drug called BLU-222, alone or with other medicines, in about 50 people with advanced solid tumors (including certain breast, ovarian, and stomach cancers). The goal was to find a safe dose and see if it shrinks tumors. However, the study was te…

This early-phase trial tested an oral drug called RP-1664 in people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effects. The study was terminated early, so full results may not be availa…

This early-stage study tested a new drug combination (TQB2223 plus penpulimab) in 22 adults with advanced liver cancer. The goal was to see if the treatment was safe and could shrink tumors. However, the trial was terminated early, so results are limited.

This early-phase study tested a new drug called BRY805 in 13 people with advanced solid tumors who had run out of standard treatment options. The main goal was to check safety and find the right dose. The trial was terminated early, so results are limited.

This study looked at whether giving the immunotherapy drug pembrolizumab (with or without axitinib) before surgery could help control advanced kidney cancer. Only 6 people took part before the study was stopped early. The goal was to see if the treatment boosted immune cells in t…

This phase 2 trial tested the drug pacritinib in 6 men whose prostate cancer had come back after surgery or radiation, shown by rising PSA levels. The goal was to see if the drug could delay further cancer growth. However, the study was terminated early, so we have limited inform…

This early-phase study tested whether adding the experimental drug NIS793 to standard chemotherapy (FOLFIRINOX) could help people with metastatic pancreatic cancer. Only 4 people took part before the study was stopped. The goal was to find a safe dose and see if the combination c…

This study tested a new drug called SOT101 (nanrilkefusp alfa) combined with pembrolizumab in 166 people with advanced solid tumors like lung, colon, and ovarian cancer. The goal was to see if the combo could shrink tumors. The trial was stopped early, so results are limited.

This early-stage study tested a new drug called BDC-3042, alone or with another drug (cemiplimab), in 17 people with advanced cancers like breast, kidney, ovarian, head and neck, colorectal, lung, or melanoma. The main goal was to check safety and find the right dose. The study w…

This trial tested a new drug called SOT102, alone or with standard chemotherapy, in 31 people with advanced pancreatic cancer. The goal was to find the safest dose and see if it helped shrink tumors. The study was stopped early because of unexpected safety problems that reappeare…

This early-stage trial tested a new drug called FAZ053, alone or with another drug (PDR001), in 154 adults with advanced solid tumors. The goal was to check safety and find the right dose by boosting the immune system to attack cancer. The study was terminated early, so full resu…

This early-phase trial tested a new drug called EO-3021, which targets a protein (CLDN18.2) found on some cancer cells. The study included 88 adults with advanced stomach or gastrointestinal cancers that had not responded to standard treatments. Participants received EO-3021 alon…

This study tested an experimental drug called SQ3370 in 53 people with advanced solid tumors that had spread or could not be removed by surgery. The goal was to check the drug's safety and find the best dose, as well as see if it could shrink tumors. The study was terminated earl…

This early-phase trial tested a drug called CPI-613 (devimistat) combined with chemotherapy and radiation for people with pancreatic cancer that cannot be surgically removed. The goal was to find the safest dose. Only 8 people took part before the study was stopped. While the app…

This study looked at whether the drug abemaciclib could help people with triple negative breast cancer that didn't respond to standard chemotherapy. The goal was to see if the drug could change the tumor's immune environment to make it more attackable by the body's defenses. The …

This study tested an oral drug called NKT2152 in people with advanced clear cell renal cell carcinoma that had worsened after other treatments. The goal was to find the safest dose and see if it could shrink tumors. The trial was terminated early, but the data may still help guid…

This study tested a new drug (NKT2152) combined with two other medicines (palbociclib and sasanlimab) in people with advanced clear cell kidney cancer that had worsened after prior treatments. The goal was to see if the combination was safe and could shrink tumors. The trial was …

This study tested a personalized treatment where a patient's own immune cells were modified in a lab to recognize and attack unique markers on their cancer cells. It involved 8 people with advanced solid tumors like lung, pancreatic, or ovarian cancer that had not responded to st…

This study looked at whether mammography and breast MRI could help identify patients with early-stage breast cancer (DCIS) who could safely receive a single dose of radiation during surgery, instead of weeks of daily radiation afterward. The goal was to avoid repeat surgeries and…

This study tested an experimental drug called ART0380 in 36 people with advanced or metastatic solid tumors, including endometrial cancer. The drug was taken by mouth and aimed to shrink tumors by blocking a protein involved in cancer cell growth. The trial was terminated early, …

This early-stage trial tested an experimental drug called NUV-868, alone or with other cancer drugs, in 82 adults with advanced solid tumors (including ovarian, pancreatic, prostate, and breast cancers). The goal was to find safe doses and check for early signs of effectiveness. …

This phase 2 study tested the drug pemigatinib in 111 people with advanced solid tumors that have specific FGFR gene mutations or translocations. The goal was to see if the drug could shrink tumors. The trial was terminated early, so the full results are not available.

This early-phase study tested the safety of an oral drug called LY3405105 in 54 people with advanced solid tumors. The trial was divided into two parts to find the right dose and to see if the drug could shrink tumors. However, the study was terminated early, meaning the drug did…

This early-phase trial tested a new drug, RP-3500 (camonsertib), combined with existing PARP inhibitors (niraparib or olaparib) in 156 adults with advanced solid tumors that have specific genetic markers. The goal was to find safe doses and see if the combination could shrink tum…

This study aimed to see if adding the experimental drug BNT321 to standard chemotherapy (mFOLFIRINOX) after surgery could help prevent pancreatic cancer from coming back. It was designed for people whose tumors were fully removed. However, the trial was stopped early after enroll…

This early-phase study tested an experimental drug called ABBV-303, alone or with another drug (budigalimab), in adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. The study was termin…

This early-phase trial tested a new drug called INCB062079 in 25 people with advanced liver cancer and other solid tumors. The main goal was to check safety and find the best dose. The study was terminated early, so results are limited.

This early-stage study tested a new drug called HFB301001 in 31 adults with advanced solid tumors (like sarcoma, kidney cancer, or melanoma) that had not responded to prior treatments. The main goal was to check the drug's safety and find the best dose. The study was terminated, …

This study tested a combination of three drugs (azacitidine, pembrolizumab, and epacadostat) in 70 people with advanced solid tumors, including lung and colorectal cancers. The goal was to see if the combination was safe and could shrink tumors. However, the trial was terminated …

This early-stage trial tested an experimental drug called LY3127804, alone or combined with another cancer drug (ramucirumab), in 62 people with advanced solid tumors. The main goal was to find a safe dose. The study was terminated early, and researchers could not determine a max…

This study tested a new way to deliver an immune-boosting drug (SD-101) directly into the liver along with standard immunotherapy for people with advanced liver cancer. It included 23 adults whose cancer had not responded to prior treatment. The goal was to find a safe dose and s…

This study tested an experimental drug called INCB057643 in 137 people with advanced cancers that had stopped responding to standard treatments. The goal was to find a safe dose and check for side effects, both when given alone and with other cancer drugs. The trial was terminate…

This early-phase trial tested a new drug called ASP2074 in 23 adults with advanced solid tumors that had spread or couldn't be removed by surgery. The goal was to find a safe dose and check for side effects. The study was terminated early, so results are limited.

This study tested a new treatment for people with non-small cell lung cancer or kidney cancer that had spread to up to six spots in the body. The treatment combined a special type of radiation therapy (PULSAR) with immunotherapy drugs (pembrolizumab or nivolumab), with or without…

This early-stage study tested a new drug called ZL-1218, alone or with another cancer drug, in 34 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, side effects, and how the drug moves through the body. The …

This early-stage study tested an experimental drug called INCB099318 in people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and how the body processes it. The study was terminated early, so results are…

This phase 2 trial tested a drug called Taxoprexin (DHA-paclitaxel) in 13 people with advanced liver cancer that had not responded to prior treatments. The goal was to see if the drug could shrink tumors and how safe it was. The study was terminated early, so results are limited.

This early-stage study tested a new drug called ACTM-838 in 10 people with advanced solid tumors that no longer responded to standard treatments. The main goals were to check safety and find the right dose. The study was stopped early, so results are limited.

This phase II trial tested whether adding either BMS-986253 or cabiralizumab to the immunotherapy drug nivolumab could shrink tumors better than nivolumab alone in people with advanced liver cancer. Only 13 participants were enrolled before the study was terminated. The goal was …

This study tested whether adding the experimental drugs NIS793 (with or without spartalizumab) to standard chemotherapy could help people with metastatic pancreatic cancer that had not been treated before. The trial enrolled 164 adults and aimed to see if the combinations slowed …

This early-phase study tested an experimental drug called AMG 199 in adults with advanced stomach, gastroesophageal junction, colorectal, or pancreatic cancers that have a specific protein (MUC17). The main goals were to check safety and find the best dose. The study was stopped …

This study tested a new drug called DKN-01 combined with tislelizumab and chemotherapy for people with advanced stomach or gastroesophageal junction cancer that could not be removed by surgery. The trial enrolled 247 adults who had not received prior treatment or whose cancer had…

This phase 2 trial tested the drug futibatinib in 115 people with advanced solid tumors or blood cancers that have specific FGFR gene changes. The goal was to see if the drug could shrink tumors or cause remission. The study was terminated early, so final results are not yet clea…

This study looked at whether men with prostate cancer could take a lower dose of the drug abiraterone (combined with prednisone) and still control their cancer. About 50 men who had never taken abiraterone before were enrolled. The goal was to find the smallest dose that still lo…

This phase 2 trial tested the drug tovorafenib (DAY101) in 23 people aged 12 and older with recurrent or progressive solid tumors that have specific genetic changes in the MAPK pathway. The goal was to see how many patients' tumors shrank or disappeared. The study was terminated …

This phase 2 trial tested a drug called tusamitamab ravtansine, alone or with chemotherapy (gemcitabine), in 50 people with advanced breast or pancreatic cancers that have a specific marker (CEACAM5). The goal was to see if the drug could shrink tumors. The study was terminated e…

This early-phase study tested the drug INCB086550 in 3 Japanese patients with advanced solid tumors that had stopped responding to other treatments. The main goal was to check safety and find the right dose. The study was terminated early, so we have limited information on how we…

This early-phase trial tested an experimental oral drug called NKT3447 in 23 adults with advanced or metastatic solid tumors that had stopped responding to standard treatments. The goal was to check safety, find the right dose, and see if the drug could shrink tumors. The study w…

This phase 2 trial tested two drugs—ulixertinib and hydroxychloroquine—in 47 people with advanced gastrointestinal cancers that have certain genetic mutations (MAPK pathway). The goal was to see if the combination could shrink tumors. However, the study was terminated early, so t…

This early-phase trial tested a new drug called STRO-002 combined with Avastin (bevacizumab) in 58 people with advanced ovarian, fallopian tube, or primary peritoneal cancer. The main goals were to check safety and find the right dose. The study was terminated early, so while it …

This early trial tested the safety and effectiveness of radioactive beads (Holmium-166 microspheres) in 4 adults with liver cancer that could not be removed by surgery or transplant. Participants first received a small scout dose to check for proper placement, then a personalized…

This early study tested an experimental oral drug called IK-595 in people with advanced solid tumors that have specific RAS or RAF gene mutations. The goal was to check safety, dosing, and early signs of tumor shrinkage. The study was terminated before completion, so full results…

This early-phase trial tested a new drug called BGB-30813, either alone or combined with the immunotherapy tislelizumab, in 44 people with advanced solid tumors that had not responded to standard treatments. The main goals were to check safety, find the right dose, and see if the…

This early-phase trial tested a drug called RiMO-401, injected directly into tumors and followed by radiation, in people with advanced cancers that had not responded to standard treatments. Only 5 patients were enrolled before the study was terminated. The main goal was to find a…

This early-stage trial tested a new drug, PF-07820435, alone or with another immunotherapy (sasanlimab) in 9 people with advanced solid tumors like lung, skin, or kidney cancer. The main goals were to check safety and find the right dose. The study was terminated early, so result…

This early-phase study tested an experimental drug called KD033 (SAR445710) in 45 adults with advanced or metastatic solid tumors. The main goal was to check safety and find the right dose, while also looking for any anti-cancer effects. The trial was terminated, so final results…

This early-phase study tested an experimental drug called BMS-986258, alone or combined with the immunotherapy nivolumab (Opdivo), in 92 people with advanced solid tumors like lung, kidney, or breast cancer. The main goal was to check safety and find the right dose. However, the …

This phase 2 trial tested a personalized cancer vaccine called TLPO in 63 people with various solid tumors. The vaccine was made from a patient's own tumor material to train their immune system to fight the cancer. The study aimed to see if the vaccine could delay disease progres…

This early-phase trial tested a new drug called LB4330 in people with advanced solid tumors that had stopped responding to standard treatments. LB4330 is designed to help the immune system attack cancer cells. The study aimed to find a safe dose and check for side effects, but it…

This phase 2 trial tested a new drug combination (NUFIRI-bev) against the standard treatment (FOLFIRI-bev) in 171 people with metastatic colorectal cancer that had already been treated. The goal was to see if the new combo could delay cancer growth better than the standard. Howev…

This early-stage trial tested an experimental drug called SAR441000, injected directly into tumors, either alone or with another drug (cemiplimab) given through a vein. The study aimed to find a safe dose and see if the combination could shrink tumors in people with advanced soli…

This study tested whether a smartphone app (Craving-to-Quit) or group mindfulness sessions work better for helping cancer survivors stop smoking. Participants also used nicotine patches. The trial was terminated early and only enrolled 20 people, so the results are not conclusive…

This early-stage trial tested a new type of immune cell therapy (ET140203 T cells) in 8 adults with advanced liver cancer that had not responded to other treatments. The therapy was designed to target a protein called AFP found on cancer cells. The study was terminated early, so …

This study tested an experimental drug called MORAb-202 in 31 people with a type of advanced lung cancer (non-small cell lung cancer adenocarcinoma) that had gotten worse after other treatments. The drug is designed to target and kill cancer cells while sparing healthy ones. The …

This early-phase trial tested an experimental drug called INCA00186, alone or with other immunotherapy drugs, in people with advanced solid tumors such as head and neck or gastrointestinal cancers. The study aimed to find safe doses and check for early signs of effectiveness. It …

Researchers are testing a nonlinear microscope (NLM) that images breast tissue during lumpectomy without the usual slide preparation. The goal is to see if the NLM can help surgeons find close or positive margins right away, so fewer patients need a second operation. The trial en…

This pilot study asks whether a blood marker called procalcitonin can help predict bacteremia—a serious bacterial infection in the blood—in children with cancer who develop a fever. Currently, doctors rely on blood cultures, which can take up to 48 hours or give false negatives. …

This trial tests whether a special imaging scan using a small amount of radioactive iodine (iodine-123) can tell the difference between benign and cancerous thyroid nodules before surgery. Currently, biopsy alone can't always make that call, so many people undergo surgery just to…

This early-phase trial is testing whether a new radioactive tracer called 18F-Clofarabine (CFA) can be used in PET scans to measure an enzyme activity in cancer cells that may predict how well certain drugs like gemcitabine work. Four adults with metastatic cancer will receive th…

This early-phase trial tested a radioactive imaging agent called 68GaNOTA-Anti-MMR-VHH2 to see if it could safely highlight tumors on PET scans. It involved 13 adults with advanced solid tumors, breast cancer, or melanoma. The study was terminated early, so we have limited inform…

This study tested a new imaging technique called AWSM-PET/CT that adds a few minutes to a standard PET/CT scan to get clearer pictures of small cancer spots. Researchers planned to enroll cancer patients to see if the new method improved accuracy. However, the study was stopped e…

This pilot study tested whether a special PET scan (FDG-PET/CT) can detect hidden heart inflammation in cancer patients receiving immune checkpoint inhibitors (ICIs). The goal was to catch this inflammation early, before it becomes severe. Only 2 participants were enrolled, and t…

This study looked at whether tiny bits of RNA in the blood can serve as markers for liver disease and liver cancer. Researchers collected blood samples from nearly 1,900 people with liver cancer, cirrhosis, or chronic liver disease. The goal was to see if these RNA markers could …

This study looked at whether a blood test that detects circulating tumor cells (CTCs) could diagnose pancreatic cancer. Researchers planned to compare the blood test results with standard tissue biopsies in 101 people with pancreatic tumors. The trial was terminated early, so the…

This early study tested a special dye called VGT-309 that makes cancer cells glow during a colonoscopy. The goal was to see if it is safe and helps doctors find colorectal tumors more easily. The study was stopped early and included 9 adults with colorectal cancer.

This study tested a new method to improve liver biopsies for people with suspected liver cancer. It combined a GPS-like tracking system with a special dye (ICG) that makes cancer cells glow. Seven adults participated, and the goal was to see if this combination could help doctors…

This early-phase trial tested a radioactive imaging agent called 68Ga-FF58 in 14 adults with certain advanced solid tumors (glioblastoma, brain metastases from breast cancer, gastroesophageal cancer, or pancreatic cancer). The goal was to see if the agent could help detect these …

This study aimed to see if a tamoxifen skin gel could work as well as the pill to lower breast cancer risk in women with certain high-risk breast conditions. The trial enrolled 65 women and compared short-term changes in breast tissue. However, the study was terminated early, so …

This study compared two standard drugs—olanzapine and dexamethasone—for preventing nausea and vomiting caused by chemotherapy. Researchers wanted to see if olanzapine could work as well as the steroid dexamethasone, potentially allowing patients to avoid steroid side effects. The…

This study tests whether a special low-calorie, plant-based diet that mimics fasting can reduce common side effects like rash, diarrhea, and fatigue in cancer patients receiving immunotherapy. Ten adults with advanced cancer will follow the diet and report their symptoms. The goa…

This study tested a short course of targeted radiation (IMRT) given over one week before surgery for rectal cancer. The goal was to see if this approach could reduce side effects like bowel problems and improve quality of life compared to standard longer treatments. Only 2 people…

This study tests a program where older adults with advanced cancer and their caregivers talk about their lives together. The goal is to see if this approach is practical and helps improve emotional well-being and relationship quality. About 60 patient-caregiver pairs will be rand…

This small pilot study tested whether applying acupressure to the ear could help improve appetite and prevent weight loss in people with advanced stomach, esophagus, or pancreatic cancer. The approach uses small adhesive pellets placed on specific ear spots to stimulate the nervo…

This study tested fezolinetant, a drug that blocks a brain receptor involved in temperature control, to see if it reduces hot flashes and night sweats in women with breast cancer taking hormone therapy. Nine participants were enrolled before the trial was stopped early. The goal …

This study tested whether a digital platform could improve collaborative care for depression in cancer patients. About 300 adults receiving cancer treatment with significant depression symptoms were enrolled. The platform aimed to help care managers track symptoms and coordinate …

This trial compared two ways of giving pelvic radiotherapy after surgery for endometrial cancer: standard 3D planning versus a newer technique called IMRT. The goal was to see if IMRT could reduce side effects like bladder and bowel problems. The study enrolled 92 participants bu…

This study looked at whether a supplement called Q-Urol (made from quercetin, bromelain, rye flower pollen, and papain) could reduce prostate inflammation caused by radiation therapy in men with localized prostate cancer. Ten men who had brachytherapy (with or without other radia…

This study tested whether a 12-week program of walking and resistance exercises or nutrition education could reduce nerve pain caused by platinum chemotherapy. The trial enrolled 36 adults with cancer who were receiving oxaliplatin or cisplatin. The study was terminated early, so…

This study tested two educational programs for parents with late-stage cancer who have children aged 5 to 17. The programs were designed to improve parent-child relationships and boost parents' confidence in talking about cancer with their kids. Researchers hoped to reduce anxiet…

This study tested whether the antidepressant escitalopram could reduce depression in people with localized pancreatic or related cancers who were receiving chemotherapy before surgery. Only 4 participants enrolled before the trial was stopped. The goal was to measure changes in d…

This phase 2 trial tested whether adding MR-guided radiation to standard chemotherapy could reduce pain in people with metastatic pancreatic cancer. Only 9 participants were enrolled before the study was terminated early. The main goal was to track pain scores over time, but the …

This study tested a drug called anamorelin to see if it could help prevent weight loss and improve appetite in people with advanced pancreatic cancer who were starting chemotherapy. The trial planned to include about 100 participants but was stopped early after only 4 people enro…

This study tested whether a digital health app (Roche DPM Module) helps cancer patients manage symptoms and reduce healthcare visits while on systemic treatment. About 49 participants used the app alongside standard care. The trial was terminated early, so results are limited.

This study tested an online support group for young adults (ages 18-39) who had cancer treatment and were feeling anxious or distressed during the COVID-19 pandemic. The goal was to see if teaching healthy coping skills through a virtual group could improve their mood and confide…

This study tested whether providing palliative care at home, through a team of doctors, nurses, social workers, and chaplains, could improve symptoms and quality of life for people with advanced cancer, heart failure, or COPD. The plan was to enroll over 1,100 patients, but the t…

This small, early-stage trial tested a drug called imsidolimab for treating acne-like skin rashes that can occur in cancer patients taking certain targeted therapies. Only 4 people were enrolled before the study was stopped. Because of the very small size and early termination, w…

This early-phase study by AstraZeneca examines how the experimental drug ceralasertib is absorbed, distributed, and eliminated in people with advanced solid tumors. Participants receive the drug orally and a tiny radiolabeled intravenous dose to track its journey. Researchers mea…

This study is measuring how often a specific genetic marker (HLA-A*02:01) and a cancer-related protein (NY-ESO-1) appear in Taiwanese patients with solid tumors like head and neck, liver, lung, breast, and esophageal cancers. By understanding these frequencies, researchers hope t…

This study tested an electronic platform called eGAP that helps older cancer patients (65+) complete questionnaires about their health. The goal was to see if the platform was easy to use and practical for patients, caregivers, and doctors. The study was terminated early after en…

This study aimed to see if COVID-19 vaccines cause more side effects in cancer patients receiving immunotherapy. Researchers planned to track 125 patients from several hospitals in France, recording any local or systemic side effects. The study was terminated early, so the full r…

This study looked at why minority cancer patients often don't take part in clinical trials. Researchers surveyed patients about their understanding and attitudes, then tested an educational video and booklet to see if it boosted enrollment. The goal was to create a personalized p…

This study looked at whether a specific gene mutation (HSD3B1) changes how well the hormone therapy letrozole works in postmenopausal women with early-stage, hormone-sensitive breast cancer. Researchers measured changes in tumor markers before and after treatment. The trial was e…

This study tested whether a visual consent form with pictures helps patients with cancer or Alzheimer's understand research better than standard text. Researchers planned to enroll 266 adults across three U.S. sites. The trial was terminated early, so results may be limited.

This pilot study aimed to find genetic differences, called microRNAs, that might explain why some pancreatic cancer patients lose muscle mass (cachexia). Researchers planned to analyze tumor samples from 40 patients undergoing surgery, focusing on African Americans who may be at …

This study tested whether consumer movement trackers could provide a more precise measure of cancer patients' physical abilities than the standard ECOG score, which relies on a doctor's observation. Researchers enrolled 41 cancer patients and used a Kinect device to record their …

This study looked at how cancer patients experience being rotated horizontally in the Nano-X system. 43 patients completed questionnaires about anxiety and motion sickness before and after rotation. The study was terminated early, so findings are limited.

This study looked at whether two tiny molecules, called miR-221 and miR-222, can be found in the blood of people with liver cancer. Researchers wanted to see if these molecules could help diagnose the disease without needing a liver biopsy. The study was very small, with only 10 …

This study aimed to see if a simple blood test could predict memory and thinking problems in men with prostate cancer receiving hormone therapy (ADT). Researchers planned to follow 32 men over time, comparing those on ADT to those not on it. The study was stopped early, so result…

This study looked at whether adding a polygenic risk score (a genetic test) to standard breast cancer risk tools helps African American and Hispanic women make better decisions about screening and prevention. Researchers enrolled 19 women at higher risk for breast cancer. The stu…

This study aimed to screen cancer patients for genetic markers before they joined other clinical trials, hoping to save time and improve drug dosing. Only 8 adults were enrolled before the study was terminated early. The approach was meant to help match patients to the right tria…

This study explored whether a wearable brain scanner (fNIRS) could objectively measure pain in cancer patients and survivors. It also tested if virtual reality (VR) relaxation could help reduce pain. The study included 106 participants, including healthy volunteers and cancer pat…

This study aimed to see if the amount of sunitinib in the blood affects side effects and how well the drug works in people with metastatic kidney cancer. Researchers planned to collect extra blood samples during routine visits from patients starting sunitinib as their first treat…

This study looked at how the cancer drug tazemetostat is processed in the body of people with advanced solid tumors who also have moderate or severe liver impairment. Researchers compared drug levels in these patients to those with normal liver function. The trial was terminated …

This study aimed to find genetic and lifestyle factors that increase stomach cancer risk in a mostly Hispanic population in South Texas. Researchers compared DNA from cancer tissue and saliva, and surveyed patients about diet, health history, and exposures. The goal was to unders…

This pilot study aimed to understand how brown adipose tissue (brown fat) might contribute to weight loss in cancer patients. Researchers planned to measure energy use in patients with and without active brown fat. However, the study was terminated early and only enrolled 3 parti…

This pilot study tested whether a new PET imaging tracer called [18F]F-AraG could track immune T cells inside tumors of patients with advanced solid cancers who were receiving immunotherapy. Nine patients were enrolled to have PET scans and tumor biopsies before and after treatme…

This study looked at whether the types of bacteria in a person's gut before treatment could predict how well their rectal tumor responds to chemotherapy and radiation. Researchers collected stool samples from 2 patients with stage II or III rectal cancer and compared their gut ba…

This study followed 28 adults with liver, colorectal, melanoma, or kidney cancers who received high-dose radiation therapy. Researchers collected blood samples before, during, and after treatment to track immune cells and other markers. The goal was to learn how the immune system…

This study tested a new lab method (RAD51 assay) to see if it could identify ovarian cancer patients whose tumors are vulnerable to the drug olaparib, even if they don't have BRCA gene mutations. The goal was to find a larger group of patients who might benefit from this treatmen…

This study used PET scans to track where a new antibody drug (S095012) goes in the body and in tumors of people with advanced solid cancers. Only 3 participants were enrolled before the study was stopped early. The goal was to understand how the drug spreads and targets tumors, n…

This study looked at genetic mutations in tumors from 565 people with advanced gastrointestinal cancers, including liver, bile duct, gallbladder, pancreas, esophagus, and stomach cancers. The goal was to see how often these mutations could be targeted by existing drugs and to tra…

This study aimed to see if a simple blood test (liquid biopsy) could help doctors make better treatment decisions for people with advanced cancers of the colon, pancreas, or bile duct. Researchers planned to enroll about 130 participants but stopped early with only 16 enrolled. T…

This study aimed to see if a radioactive tracer could measure radiation doses in tumors and organs for people with recurrent or metastatic adenoid cystic carcinoma that cannot be surgically removed. Only one participant was enrolled before the study was terminated. The main goal …

This study aimed to create a registry of tissue and blood samples from 1,000 patients undergoing surgery or biopsy for liver or bile duct tumors. The samples were stored for future research to better understand these cancers and develop new treatments. The study was terminated ea…

This study collected fluid from the abdomen or lungs, plus blood, from 22 adults with solid tumors. The goal was to learn more about cancer biology, not to provide a direct treatment. Researchers hope these samples will help them understand how cancer grows and lead to better the…

This study looked at whether a special type of MRI, called Arterial Spin Labeling, can measure blood flow changes in kidney cancer tumors as early as two weeks after starting treatment. The goal was to see if this could help doctors know sooner whether a treatment is working. The…

This study aimed to see if certain immune cells in the blood could predict which patients with advanced liver cancer would benefit from a combination of immunotherapy drugs (Atezolizumab and Bevacizumab). Researchers planned to measure these cells before and after starting treatm…

This study looked at whether DNA markers found in urine can help detect prostate cancer. Researchers collected urine and prostate fluid samples from 24 men with or suspected of having prostate cancer. The goal was to see how accurate these markers are and to understand patient op…

This study tested whether combining two types of scans (PSMA-PET and MRI) can help doctors better target radiation for prostate cancer. The goal was to see if this approach is safe and possible. Only 8 people took part before the study was stopped early.

This study aimed to understand how COVID-19 affects people with cancer, especially those receiving treatment. Researchers planned to measure how many cancer patients had COVID-19 without symptoms and how their immune systems responded. The study was terminated early, so results a…

This study looked at the genetics of people with multiple lung tumors (multifocal lung adenocarcinoma). Researchers collected tissue and blood samples from 100 participants during surgery to analyze their DNA. The goal was to see if genetic information could help guide treatment …

This study tested a special type of scan (SPECT/CT) to see how well it measures liver function in people with liver cancer who are getting radiation or surgery. The goal was to learn if this scan can help doctors see which parts of the liver are working well before, during, and a…

This study looked at how adults with advanced or metastatic solid tumors absorb, break down, and remove the drug subasumstat. Only 3 people took part, and the study was stopped early. The goal was to measure the drug in urine and stool, not to test if it works as a treatment.

This study tested a new 3D scanner to measure how the brain shifts during surgery for epilepsy or tumor removal. Only one person took part before the study was stopped. The goal was to see if the scanner could accurately track brain surface changes over time, which could help sur…

This study looked at whether giving the drug palbociclib before surgery could cause changes in breast tissue in people with ductal carcinoma in situ (DCIS), a very early form of breast cancer. It planned to enroll 24 participants, but was stopped early after only 17 joined. The m…

This pilot study tested a device called BioTraceIO 360, designed to help doctors plan and monitor procedures that destroy liver tumors using heat. The study planned to enroll 30 people with liver cancer, but only 4 participated before it was stopped early. Researchers looked at w…

This study looked at the safety of the cancer drug nivolumab in people with metastatic kidney cancer who also have kidney failure. Researchers planned to compare side effects in 81 patients with different levels of kidney function. However, the study was terminated early, so the …

This study tested whether wearable fitness trackers (like Fitbits) and smartphone diaries can give a more accurate picture of cancer patients' physical function than standard doctor assessments. Researchers enrolled 31 cancer patients starting early-phase clinical trials. The goa…